How To Calculate Qalys

Calculate Quality-Adjusted Life Years (QALYs) to measure the value of health outcomes. This tool helps economists, policymakers, and healthcare professionals evaluate medical interventions.

Comprehensive Guide: How to Calculate QALYs (Quality-Adjusted Life Years)

Quality-Adjusted Life Years (QALYs) are the standard metric used in health economics to quantify the value of health outcomes. One QALY equates to one year of life in perfect health. This measure combines both the quantity and quality of life, making it invaluable for comparing different medical interventions and healthcare policies.

The QALY Formula

The fundamental QALY calculation multiplies life years by a utility value representing health quality:

QALY = Life Years × Utility Value
Discounted QALY = Σ (Utility × (1/(1+r)^t))

Where:

• Life Years: Duration of life extension or health improvement
• Utility Value: Health state quality (0 = death, 1 = perfect health)
• r: Discount rate (typically 3% annually)
• t: Time period

Step-by-Step Calculation Process

1. Determine Life Years Gained

   Calculate the difference in life expectancy between the intervention and standard care. For example, if a new cancer drug extends life by 5 years compared to existing treatments, the life years gained would be 5.

2. Assign Utility Values

   Use standardized health state classifications to assign utility values. Common sources include:

   • EQ-5D (EuroQol 5-Dimension)
   • SF-6D (Short Form 6-Dimension)
   • HUI (Health Utilities Index)

   For example, a patient with moderate mobility problems but no other issues might have a utility value of 0.85.

3. Apply Time Preferences

   Most economic evaluations apply discounting to future QALYs. The standard discount rate is 3% annually, though this varies by country:

   Country	Standard Discount Rate	Source
   United States	3%	Panel on Cost-Effectiveness in Health and Medicine
   United Kingdom (NICE)	3.5%	National Institute for Health and Care Excellence
   Canada	5%	Canadian Agency for Drugs and Technologies in Health
   Australia	5% (base case), 1.5%-3% (sensitivity)	Pharmaceutical Benefits Advisory Committee

4. Calculate Total QALYs

   Multiply life years by utility values for each period, then sum the results. For discounted QALYs, apply the discount factor to each period’s QALY value before summing.

5. Cost-Utility Analysis

   Divide the intervention’s cost by the QALYs gained to determine cost-effectiveness:

   Cost per QALY = Total Cost / QALYs Gained

   Common thresholds for cost-effectiveness:

   • $50,000-$100,000 per QALY: Generally considered cost-effective in the US
   • $150,000+ per QALY: Often considered not cost-effective without special justification
   • £20,000-£30,000 per QALY: NICE threshold in the UK

Practical Applications of QALYs

Health Technology Assessment

Government agencies like NICE in the UK and ICER in the US use QALYs to determine which drugs and treatments should be covered by national health services or insurance plans.

Resource Allocation

Hospitals and health systems use QALY calculations to prioritize investments in equipment, staffing, and facilities based on which options provide the most health benefit per dollar spent.

Vaccine Prioritization

During the COVID-19 pandemic, QALY models helped determine which population groups should receive vaccines first to maximize societal health benefits.

Common Challenges in QALY Calculation

1. Utility Value Subjectivity

   Different instruments (EQ-5D, SF-6D) may produce different utility values for the same health state. A 2019 study in Value in Health found that EQ-5D and SF-6D differed by an average of 0.08 utility points across 6,000 patients.

2. Discount Rate Controversies

   The choice of discount rate significantly impacts results. A 2021 analysis in Health Economics showed that changing the discount rate from 3% to 1.5% increased the present value of QALYs by 37% over 30 years.

3. Equity Considerations

   Standard QALY calculations don’t account for equity concerns (e.g., prioritizing treatments for disadvantaged groups). Some countries apply equity weights to address this limitation.

4. End-of-Life Preferences

   Many people value life extension more highly when near death, but standard QALY models don’t incorporate these preferences. Some economists propose “severity weights” to address this.

Advanced QALY Concepts

Probabilistic Sensitivity Analysis

Uses Monte Carlo simulations to account for uncertainty in input parameters. A 2020 study in Medical Decision Making found that 43% of cost-effectiveness conclusions changed when using PSA versus deterministic analysis.

Value of a Statistical Life (VSL)

An alternative metric that estimates how much people are willing to pay for small reductions in mortality risk. EPA uses $10.9 million per statistical life (2020 dollars) for regulatory analysis.

DALYs (Disability-Adjusted Life Years)

Used by the World Health Organization, DALYs measure years lost to premature death and disability. Unlike QALYs, DALYs focus on burden of disease rather than health gains.

QALYs in Different Healthcare Systems

Country/Organization	QALY Threshold (per QALY)	Key Features	Source
UK (NICE)	£20,000-£30,000	Uses EQ-5D-3L for utility values; considers end-of-life premium	NICE Guidelines
US (ICER)	$50,000-$150,000	Uses range of thresholds; considers budget impact	ICER Value Frameworks
Australia (PBAC)	A$45,000-A$75,000	Uses 1.5%-5% discount rates; considers equity	PBAC Guidelines
Canada (CADTH)	C$50,000-C$100,000	Uses 5% discount rate; considers severity of disease	CADTH Guidelines
WHO (Global)	1-3× GDP per capita	Uses DALYs more commonly; focuses on low-income countries	WHO Choice

Ethical Considerations in QALY Use

While QALYs provide a quantitative approach to health valuation, their use raises several ethical questions:

• Age Discrimination: QALY models may undervalue treatments for elderly patients who have fewer remaining life years
• Disability Bias: Some argue that QALYs inherently discriminate against people with disabilities by assigning lower utility values to their health states
• Rare Disease Challenges: Treatments for rare diseases often appear less cost-effective due to small patient populations, even when providing substantial benefits to individuals
• Cultural Variations: Utility values may not reflect cultural differences in health preferences and quality-of-life perceptions

The US Panel on Cost-Effectiveness in Health and Medicine recommends several approaches to address these ethical concerns, including:

• Using reference case analyses with sensitivity analyses for different perspectives
• Incorporating equity weights for disadvantaged populations
• Considering severity of disease in threshold determinations
• Engaging patient and community representatives in utility valuation

Future Directions in QALY Research

Emerging areas of research are addressing current limitations of QALY methodology:

1. Dynamic Utility Assessment

   New methods capture how utility values change over time as patients adapt to health conditions. A 2022 study in Journal of Health Economics found that utility values for chronic conditions increased by 0.05-0.15 over 5 years as patients adapted.

2. Machine Learning Applications

   AI models can predict individual-level utility values more accurately than population averages. Google Health’s 2021 study showed a 22% improvement in utility prediction using ML models trained on electronic health records.

3. Patient-Reported Outcome Measures (PROMs)

   Direct incorporation of patient-reported data into utility calculations. The FDA’s 2020 guidance encourages using PROMs in regulatory submissions.

4. Social Value Judgments

   Explicit incorporation of societal values into QALY calculations. The UK’s NICE now includes “severity modifiers” that increase QALY weights for life-extending treatments in terminal illnesses.

Practical Example: Calculating QALYs for a New Cancer Drug

Let’s walk through a complete example using our calculator:

1. Scenario: A new lung cancer drug extends life by 2.5 years compared to standard care. Patients on the drug have a utility value of 0.75 (some pain and mobility issues but generally functional).
2. Inputs:
   • Life years gained: 2.5
   • Utility value: 0.75
   • Discount rate: 3%
   • Time horizon: 2.5 years (same as life extension)
3. Calculation:

   Year 1: 1 × 0.75 = 0.75 QALYs

   Year 2: 1 × 0.75 × (1/1.03) ≈ 0.728 QALYs

   Year 0.5: 0.5 × 0.75 × (1/1.03)² ≈ 0.353 QALYs

   Total discounted QALYs ≈ 1.831

4. Cost-Effectiveness:

   If the drug costs $120,000 for the full course:

   $120,000 / 1.831 QALYs ≈ $65,538 per QALY

   This would be considered cost-effective in most health systems.

Tools and Resources for QALY Calculation

EQ-5D Value Sets

The EuroQol Group provides country-specific value sets for converting EQ-5D responses to utility values. Visit EuroQol

SF-6D Algorithm

The SF-6D is derived from the SF-36 and SF-12 health surveys. The official scoring algorithm is available from the University of Sheffield. Sheffield MVH Group

Tufts CEA Registry

Database of cost-effectiveness analyses with QALY outcomes. Contains over 7,000 studies. Tufts CEA Registry

Frequently Asked Questions

Why do we discount future QALYs?

Discounting reflects several economic realities:

• Time preference: People generally prefer benefits now rather than later
• Uncertainty: Future health benefits are less certain
• Opportunity cost: Resources could be invested elsewhere to produce immediate benefits

The US Panel on Cost-Effectiveness recommends 3% discounting for both costs and health effects.

How are utility values determined?

Utility values are typically derived through:

1. Standard Gamble: Participants choose between a certain intermediate health state and a gamble between perfect health and death
2. Time Trade-off: Participants choose between living in a impaired health state for a longer time or perfect health for a shorter time
3. Visual Analog Scale: Participants rate health states on a 0-100 scale (though this is less preferred for QALY calculations)

These methods are conducted with representative population samples to create value sets.

Can QALYs be used for individual patient decisions?

While QALYs are primarily a population-level tool, some clinicians use them to:

• Explain treatment trade-offs to patients
• Prioritize shared decision-making discussions
• Identify when patient preferences diverge from population averages

However, the American Medical Association cautions against using QALYs as the sole basis for individual treatment decisions.